Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial

Objective In the SENSCIS trial in subjects with systemic sclerosis–associated interstitial lung disease (SSc‐ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categori...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Arthritis & rheumatology (Hoboken, N.J.) Ročník 73; číslo 4; s. 671 - 676
Hlavní autori:	Maher, Toby M., Mayes, Maureen D., Kreuter, Michael, Volkmann, Elizabeth R., Aringer, Martin, Castellvi, Ivan, Cutolo, Maurizio, Stock, Christian, Schoof, Nils, Alves, Margarida, Raghu, Ganesh
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Wiley Subscription Services, Inc 01.04.2021 John Wiley and Sons Inc
Predmet:	Adult Aged Confidence intervals Death Disease Progression Double-Blind Method Double-blind studies Female Full Length Humans Indoles - pharmacology Indoles - therapeutic use Lung - drug effects Lung - physiopathology Lung diseases Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Lung Diseases, Interstitial - physiopathology Male Middle Aged Mortality Placebos Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Respiratory function Scleroderma Scleroderma, Systemic - complications Scleroderma, Systemic - physiopathology Systemic Sclerosis Treatment Outcome
ISSN:	2326-5191, 2326-5205, 2326-5205
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!